BEAM (Beam Therapeutics) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BEAM Beam Therapeutics Inc BEAM
71 GF Score
Price $27.57
GF Value $28.11
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BEAM vs KOD, TARS, VERA: Short Percentage of Float Comparison

For the Biotechnology subindustry, Beam Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beam Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Beam Therapeutics's Short Percentage of Float falls into.


BEAM
71GF Score
Beam Therapeutics Inc BEAM
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beam Therapeutics (BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued. The current stock price of $27.57 is trading 1.9% below its estimated GF Value™ of $28.11. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for BEAM:

  • Short Percentage of Float:
  • GF Value™: $28.11 vs. price of $27.57 (1.9% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:Mexico
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
71GF Score

Get the complete analysis for BEAM

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.57
Price
$28.11
GF Value